

Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.08.2024
2.5	28.09.2024	6064051-00018	Date of first issue: 19.06.2020

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Atinvicitinib Formulation
1.2	Relevant identified uses of th	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
	Company	:	MSD
			Kilsheelan
			Clonmel Tipperary, IE
	Telephone	:	353-51-601000
	E-mail address of person	:	EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Not a hazardous substance or mixture.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.



Atinvicitinib Formulation

Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 14.08.2024
2.5	28.09.2024	6064051-00018	Date of first issue: 19.06.2020

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		
	Registration number		
atinvicitinib	2169273-59-8		>= 1 - < 10

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders	:	No special precautions are necessary for first aid responders.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In case of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks :	:	Contact with dust can cause me	nechanical	irritation o	or drying of
---------	---	--------------------------------	------------	--------------	--------------



Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024		S Number: 64051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020
			the skin. Dust contact wi	th the eyes can lead to mechanical irritation.
4.3 Indica	ation of any immediate	mec	lical attention a	nd special treatment needed
Trea	tment	:	Treat symptom	atically and supportively.
SECTIO	N 5: Firefighting meas	sure	es	
5.1 Extin	guishing media			
Suita	ble extinguishing media	:	Water spray Alcohol-resistar Carbon dioxide Dry chemical	
Unsu medi	uitable extinguishing a	:	None known.	
5.2 Speci	al hazards arising from	the	substance or r	nixture
Spec fighti	sific hazards during fire- ng	:	concentrations, potential dust e	ng dust; fine dust dispersed in air in sufficient and in the presence of an ignition source is a xplosion hazard. mbustion products may be a hazard to health.
Haza ucts	ardous combustion prod-	:	Carbon oxides Metal oxides	
5.3 Advio	e for firefighters			
Spec	cial protective equipment refighters	:		ained breathing apparatus for firefighting if nec- rsonal protective equipment.
Spec ods	cific extinguishing meth-	:	cumstances an Use water spra	ng measures that are appropriate to local cir- d the surrounding environment. y to cool unopened containers. naged containers from fire area if it is safe to de

6.1 Personal precautions, protective equipment and emergency procedures

or resonal precoutions, protective equipment and emergency procedures			
Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).	

6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
		Prevent further leakage or spillage if safe to do so.
		Retain and dispose of contaminated wash water.
		Local authorities should be advised if significant spillages



Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 6064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020
		cannot be conta	ained.
6.3 Metho	ds and material for c	ontainment and clea	ning up
Metho	ods for cleaning up	tainer for dispos Avoid dispersal with compresse Dust deposits s es, as these ma leased into the Local or nationa posal of this ma employed in the mine which reg Sections 13 and	of dust in the air (i.e., clearing dust surfaces

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

in i rooddallono for ouro nanaling	
Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe dust.
, lavies on sale handling	Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation.
	Keep container closed when not in use.
	Keep away from heat and sources of ignition.
	Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
	The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
7.2 Conditions for safe storage, in	ncluding any incompatibilities

Requirements for storage	:	Keep in properly labelled containers. Store in accordance with
areas and containers		the particular national regulations.



Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024		DS Number: 064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020
Advice	on common storage	:	Do not store with Strong oxidizing a	the following product types: agents
7.3 Specific end use(s) Specific use(s)		:	No data available	

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

dusts non-specific

Occupational Exposure Limits

4 mg/m3
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable
dust)
Basis: IE OEL

10 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
atinvicitinib	2169273- 59-8	TWA	80 ug/m3 (OEB 3)	Internal
		Wipe limit	800 ug/100cm2	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves



Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 6064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020				
Remarks Skin and body protection		: Work uniform Additional bod task being per	 Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. 				
Respiratory protection		contaminated If adequate loc sure assessm ommended gu Equipment sho	Use appropriate degowning techniques to remove potentially contaminated clothing. If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143				
Filt	ter type	: Particulates ty	pe (P)				

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	off-white
Odour	:	odourless
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
рН	:	No data available
Viscosity		



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

Atinvicitinib Formulation

Vers 2.5	sion	Revision Date: 28.09.2024		S Number: 64051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020		
	Vise	cosity, kinematic	:	Not applicable			
		ity(ies) ter solubility	:	No data availabl	e		
		n coefficient: n- I/water	:	Not applicable			
	Vapou	r pressure	: Not applicable				
Relative density		: No data available					
	Density		:	0.2 - 0.9 g/cm ³			
Relative vapour density		:	: Not applicable				
		e characteristics ticle size	:	No data available	e		
9.2		nformation					
	Explos	ives	:	Not explosive			
	Oxidizi	ng properties	:	The substance of	r mixture is not classified as oxidizing.		
	Evapo	ration rate	:	Not applicable			
	Molecu	ılar weight	:	No data availabl	e		

SECTION 10: Stability and reactivity


10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reaction	ons
Hazardous reactions :	May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid :	Heat, flames and sparks. Avoid dust formation.
10.5 Incompatible materials	
Materials to avoid :	Oxidizing agents





Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.08.2024
2.5	28.09.2024	6064051-00018	Date of first issue: 19.06.2020

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes Information on likely routes of : exposure	as defined in Regulation (EC) No 1272/2008 Inhalation Skin contact Ingestion Eye contact
Acute toxicity	
Not classified based on available	information.
Components:	
atinvicitinib:	
Acute oral toxicity :	Assessment: The substance or mixture has no acute oral tox- icity
	LD50 (Rat): > 2,000 mg/kg Assessment: The substance or mixture has no acute oral tox- icity
Acute dermal toxicity :	LD50 Dermal (Rat, male): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity
Skin corrosion/irritation	

Not classified based on available information.

Components:

atinvicitinib:

Species	:	human skin
Method	:	in vitro skin corrosion test
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

atinvicitinib:

Species	:	Bovine cornea
Method	:	in vitro eye irritation test
Result	:	No eye irritation
Remarks	:	No eye irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 6064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020				
Resp							
Skin sensitisation							

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

atin	vic	itin	ih.
~~~			


Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Dermal
Species	:	Mouse
Result	:	Not a skin sensitizer.

#### Germ cell mutagenicity

Not classified based on available information.

#### **Components:**

Genotoxicity in vitro       :       Test Type: Bacterial reverse mutation assay (AMES) Result: negative         Genotoxicity in vivo       :       Test Type: Micronucleus test Test system: Human lymphocytes Result: negative         Genotoxicity in vivo       :       Test Type: Micronucleus test Species: Mouse Cell type: Bone marrow Application Route: Oral Result: negative         Germ cell mutagenicity- As- sessment       :       Weight of evidence does not support classification as a germ cell mutagen.         Carcinogenicity Not classified based on available information.       :       Weight of evidence does not support classification as a germ cell mutagen.         Emponents:       :       :       Not classified based on available information.         Components:       :       :       Not classified due to lack of data.         Reproductive toxicity Not classified based on available information.       :       :         Components:       :       :         atinvicitinib:       :       :       :         Effects on fertility       :       :       Remarks: Not classified due to lack of data.	atinvicitinib:	
Test system: Human lymphocytes         Result: negative         Genotoxicity in vivo       : Test Type: Micronucleus test         Species: Mouse         Cell type: Bone marrow         Application Route: Oral         Result: negative         Germ cell mutagenicity- As-       : Weight of evidence does not support classification as a germ         cell mutagenicity       : Weight of evidence does not support classification as a germ         Carcinogenicity       : Weight of evidence does not support classification as a germ         Not classified based on available information.       : Components:         atinvicitinib:       : Not classified due to lack of data.         Reproductive toxicity       : Not classified due to lack of data.         Not classified based on available information.       : Components:         atinvicitinib:       : Not classified due to lack of data.	Genotoxicity in vitro	
Species: Mouse         Cell type: Bone marrow         Application Route: Oral         Result: negative         Germ cell mutagenicity- As-         sessment         Weight of evidence does not support classification as a germ         cell mutagen.         Carcinogenicity         Not classified based on available information.         Components:         atinvicitinib:         Remarks       :         Not classified based on available information.         Components:         atinvicitinib:         Reproductive toxicity         Not classified based on available information.         Components:         atinvicitinib:         information.		Test system: Human lymphocytes
sessment cell mutagen. Carcinogenicity Not classified based on available information. Components: atinvicitinib: Remarks : Not classified due to lack of data. Reproductive toxicity Not classified based on available information. Components: atinvicitinib:	Genotoxicity in vivo	Species: Mouse Cell type: Bone marrow Application Route: Oral
Not classified based on available information.   Components:   atinvicitinib:   Remarks   : Not classified due to lack of data.   Reproductive toxicity Not classified based on available information. Components: atinvicitinib:	<b>o</b> ,	
Components:         atinvicitinib:         Remarks       : Not classified due to lack of data.         Reproductive toxicity         Not classified based on available information.         Components:         atinvicitinib:	Carcinogenicity	
atinvicitinib:         Remarks       : Not classified due to lack of data.         Reproductive toxicity         Not classified based on available information.         Components:         atinvicitinib:		
Remarks : Not classified due to lack of data.   Reproductive toxicity   Not classified based on available information.   Components:   atinvicitinib:	Not classified based on availa	ole information.
Reproductive toxicity Not classified based on available information. Components: atinvicitinib:	_	ole information.
Not classified based on available information. Components: atinvicitinib:	Components:	ble information.
<u>Components:</u> atinvicitinib:	Components: atinvicitinib:	
atinvicitinib:	<u>Components:</u> atinvicitinib: Remarks	
	<u>Components:</u> atinvicitinib: Remarks Reproductive toxicity	: Not classified due to lack of data.
Effects on fertility : Remarks: Not classified due to lack of data.	Components: atinvicitinib: Remarks Reproductive toxicity Not classified based on availa	: Not classified due to lack of data.
	Components: atinvicitinib: Remarks Reproductive toxicity Not classified based on availa Components:	: Not classified due to lack of data.





## **Atinvicitinib Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 14.08.2024
2.5		6064051-00018	Date of first issue: 19.06.2020
Effects ment	s on foetal develop-	test Species: Rat Application Rout General Toxicity Teratogenicity: N	Maternal: NOAEL: 90

#### STOT - single exposure

Not classified based on available information.

#### STOT - repeated exposure

Not classified based on available information.

#### Repeated dose toxicity

#### **Components:**

#### atinvicitinib:

Species NOAEL Application Route Exposure time Number of exposures	 Dog, male and female 6 mg/kg Oral 6 Months Daily
Species NOAEL Application Route Exposure time Number of exposures	 Rat, male and female 5 mg/kg Oral 3 Months Daily
Species NOAEL Application Route Exposure time Number of exposures	 Rat, male and female 12 mg/kg Dermal 3 Months Daily

#### Aspiration toxicity

Not classified based on available information.

:

#### **Components:**

atinvicitinib: Not applicable

#### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### Product:

Assessment

The substance/mixture does not contain components considered to have endocrine disrupting properties according to




## **Atinvicitinib Formulation**

Version 2.5	Revision Date: 28.09.2024		DS Number: 64051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020
				7(f) or Commission Delegated regulation or Commission Regulation (EU) 2018/605 at higher.
SECTION	12: Ecological infor	ma	tion	
12.1 Toxic	ity			
<u>Comp</u>	onents:			
atinvi	citinib:			
Toxici	ty to fish	:	Exposure time: 96 Method: OECD T	
	ty to daphnia and other c invertebrates	:	Exposure time: 48 Method: OECD T	
			Exposure time: 96 Method: OPPTS 8	
Toxicit plants	ty to algae/aquatic	:	100 mg/l End point: Growth Exposure time: 72 Method: OECD T	2 h
Toxicit	ty to microorganisms	:	EC10 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD T	h ration inhibition of activated sludge
			EC50 : > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ration inhibition of activated sludge
Ecoto	xicology Assessment			
Acute	aquatic toxicity	:	No data available	
Chron	ic aquatic toxicity	:	No data available	

12.2 Persistence and degradability

No data available





## **Atinvicitinib Formulation**

Version 2.5	Revision Date: 28.09.2024	SDS Number: 6064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020
12.3 Bioa	ccumulative potential		
<u>Com</u>	ponents:		
Partit	r <b>icitinib:</b> tion coefficient: n- nol/water	: log Pow: 1.45	
	<b>ility in soil</b> ata available		
12.5 Resu	ults of PBT and vPvB a	ssessment	
<u>Prod</u> Asse	l <mark>uct:</mark> ssment	to be either per	/mixture contains no components considered sistent, bioaccumulative and toxic (PBT), or and very bioaccumulative (vPvB) at levels of
12.6 Endo	ocrine disrupting prop	erties	
Prod	uct:		
Asse	ssment	ered to have er REACH Article	/mixture does not contain components consid- ndocrine disrupting properties according to 57(f) or Commission Delegated regulation 0 or Commission Regulation (EU) 2018/605 at or higher.
	er adverse effects ata available		
SECTIO	N 13: Disposal consi	derations	
13 1 Was	te treatment methods		
Prod		According to th are not product Waste codes s discussion with	ccordance with local regulations. e European Waste Catalogue, Waste Codes specific, but application specific. hould be assigned by the user, preferably in the waste disposal authorities.

		Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han-
		dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

#### 14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

## Atinvicitinib Formulation

2.5	Revision Date: 28.09.2024	SDS Number:Date of last issue: 14.08.20246064051-00018Date of first issue: 19.06.2020			
IMDG		: Not regulated as a dangerous good			
IATA		: Not regulated as a dangerous good			
14.2 UN pr	oper shipping name				
ADN		: Not regulated as a dangerous good			
ADR		: Not regulated as a dangerous good			
RID		: Not regulated as a dangerous good			
IMDG		: Not regulated as a dangerous good			
ΙΑΤΑ		: Not regulated as a dangerous good			
14.3 Trans	port hazard class(es				
ADN		: Not regulated as a dangerous good			
ADR		: Not regulated as a dangerous good			
RID		: Not regulated as a dangerous good			
IMDG		: Not regulated as a dangerous good			
ΙΑΤΑ		: Not regulated as a dangerous good			
14.4 Packi	ng group				
ADN		: Not regulated as a dangerous good			
ADR		: Not regulated as a dangerous good			
RID		: Not regulated as a dangerous good			
IMDG		: Not regulated as a dangerous good			
ΙΑΤΑ	(Cargo)	: Not regulated as a dangerous good			
ΙΑΤΑ	(Passenger)	: Not regulated as a dangerous good			
<b>14.5 Environmental hazards</b> Not regulated as a dangerous good					
•	al precautions for us	3r			
14.7 Mariti	me transport in bulk	according to IMO instruments			
Rema	rks	: Not applicable for product as supplied.			

# 15.1 Safety, health and environmental regulations/legislation specific for the substance or mix-ture

REACH - Restrictions on the manufacture, placing on	:	Not applicable
the market and use of certain dangerous substances,		
mixtures and articles (Annex XVII)		
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		



## Atinvicitinib Formulation

Version 2.5	Revision Date: 28.09.2024	SDS Number: 6064051-00018	Date of last issue: 14.08.2024 Date of first issue: 19.06.2020				
Regulation (EC) on substances that deplete the ozone : Not applicable layer							
Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable tants (recast)							
Regulation (EU) No 649/2012 of the European Parlia- : Not applicable ment and the Council concerning the export and import of dangerous chemicals							
REAC	REACH - List of substances subject to authorisation : Not applicable						
(Annex XIV) Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable							
The components of this product are reported in the following inventories:							
DSL		: not determined					
AICS		: not determined					
IECSO	C	: not determined					
<b>15.2 Chemical safety assessment</b> A Chemical Safety Assessment has not been carried out.							

#### **SECTION 16: Other information**

Other information :	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
---------------------	--------------------------------------------------------------------------------------------------------------------------------------

#### Full text of H-Statements

#### Full text of other abbreviations

IE OEL	:	Ireland. List of Chemical Agents and Carcinogens with Occu-
		pational Exposure Limit Values - Code of Practice, Schedule 1
		and 2
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China;



### Atinvicitinib Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.08.2024
2.5	28.09.2024	6064051-00018	Date of first issue: 19.06.2020

IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### **Further information**

compile the Safety Data Sheet

Sources of key data used to : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN